EGFR and non-small cell lung carcinoma: Here, we report a successful case of combination therapy with PD-1 inhibitor (sintilimab), anti-VEGF therapy, and chemotherapy in a patient with NSCLC who developed acquired EGFR 19 exon deletion (19Del)/T790M/cis-C797S mutation resistance following progression on EGFR TKI therapy.